Perspectives in gene therapy for MS

Research output: Contribution to journalArticlepeer-review


The blood-brain barrier limits the therapeutic efficacy of systemic administration of anti-inflammatory and/or neuroprotective molecules to patients affected by immune-mediated inflammatory demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis. Drug delivery to the CNS using non-replicative viral vectors may represent a valid alternative therapeutic strategy. Gene therapy for multiple sclerosis might include different human-grade' vectors, which could be used to deliver anti-inflammatory molecules as well as neuroprotective agents into the CNS in a flexible and useful way. These potential 'therapeutic' vectors would have different life spans, tissue tropism and infectivity rates.

Original languageEnglish
Pages (from-to)84-88
Number of pages5
JournalInternational MS Journal
Issue number3
Publication statusPublished - Aug 2003


  • Blood-brain barrier
  • Gene therapy
  • Multiple sclerosis
  • Vectors

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Perspectives in gene therapy for MS'. Together they form a unique fingerprint.

Cite this